• SENSEX
    NIFTY 50
Market

Top brokerage calls for November 27: Morgan Stanley 'overweight' on HDFC; HSBC cuts target price for SpiceJet

Updated : 2019-11-27 07:59:50

SGX Nifty indicates a flat start for the Indian indices on Wednesday. It was trading 5 points or 0.03 percent lower at 12,082 at 7:35 am. However, Asian shares ticked higher on Wednesday as more upbeat signals from US-China trade talks fanned hopes of an imminent end to tariff hostilities. Among brokerages, Morgan Stanley was 'overweight' on HDFC, while HSBC cut target price for SpiceJet and Mahindra CIE. Here are the top brokerage calls for Wednesday:

<strong>Morgan Stanley on HDFC:</strong> The brokerage was 'overweight' on the stock and raised its target to Rs 2,900 from Rs 2,600 per share. Return on equity (RoE) and earnings per share (EPS) growth are poised to stage a multi-year recovery, the brokerage noted, adding that the recovery will be supported by structurally stronger positioning among non-bank lenders.
Morgan Stanley on HDFC: The brokerage was 'overweight' on the stock and raised its target to Rs 2,900 from Rs 2,600 per share. Return on equity (RoE) and earnings per share (EPS) growth are poised to stage a multi-year recovery, the brokerage noted, adding that the recovery will be supported by structurally stronger positioning among non-bank lenders.
<strong>HSBC on SpiceJet:</strong> The brokerage had a 'hold' rating on the stock but cut its target to Rs 115 per share from Rs 130 earlier. As per the brokerage, the company's Q2 results were worse than expected, however, 737Max returning to operations by March could benefit cost.
HSBC on SpiceJet: The brokerage had a 'hold' rating on the stock but cut its target to Rs 115 per share from Rs 130 earlier. As per the brokerage, the company's Q2 results were worse than expected, however, 737Max returning to operations by March could benefit cost.
<strong>HSBC on Sun Pharma: </strong>The brokerage maintained 'hold' on the stock with a target at Rs 425 per share. A potential settlement with the United States Department of Justice would remove a major overhang for generics, said the brokerage. It added that timing and outcome remain uncertain.
HSBC on Sun Pharma: The brokerage maintained 'hold' on the stock with a target at Rs 425 per share. A potential settlement with the United States Department of Justice would remove a major overhang for generics, said the brokerage. It added that timing and outcome remain uncertain.
<strong>HSBC on Mahindra CIE:</strong> The brokerage maintained 'buy' call on the stock but reduced its target to Rs 230 per share from Rs 300 earlier. End-market demand has declined steeply in recent months, the brokerage noted, adding that key segments are likely to recover in the near term.
HSBC on Mahindra CIE: The brokerage maintained 'buy' call on the stock but reduced its target to Rs 230 per share from Rs 300 earlier. End-market demand has declined steeply in recent months, the brokerage noted, adding that key segments are likely to recover in the near term.
Live TV

Ask Our Experts CNBC TV18